Omarigliptin

Omarigliptin (MK-3102) is a Dipeptidyl peptidase-4 inhibitor (DPP-4 inhibitor) drug used in the treatment of Type 2 diabetes. It was developed by Merck & Co. and approved in Japan in 2015. However, it has not been approved for use in the United States or Europe.

Mechanism of Action

Omarigliptin works by inhibiting the enzyme Dipeptidyl peptidase-4 (DPP-4). This enzyme is involved in the breakdown of Incretin hormones, which are responsible for increasing the amount of insulin released by the pancreas. By inhibiting DPP-4, Omarigliptin increases the levels of incretin hormones, leading to increased insulin release and decreased glucose levels in the blood.

Clinical Trials

Omarigliptin has undergone several clinical trials to assess its safety and efficacy in treating Type 2 diabetes. In a Phase III trial conducted in Japan, Omarigliptin was found to be effective in reducing HbA1c levels in patients with Type 2 diabetes.

Approval

Omarigliptin was approved for use in Japan in September 2015. However, in 2016, Merck & Co. announced that they would not seek approval for Omarigliptin in the United States or Europe, citing a desire to focus on other drugs in their portfolio.

Side Effects

Common side effects of Omarigliptin include Nausea, Headache, and Upper respiratory tract infection. In rare cases, it can cause Pancreatitis and Hypoglycemia.

See Also

• Dipeptidyl peptidase-4 inhibitors
• Type 2 diabetes
• Incretin
• Merck & Co.

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia